Navigation Links
Alzheimer Disease - New Drugs, Markets and Companies - 2013
Date:3/19/2013

et of Alzheimer's disease is being recognized.

Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Selected 185 clinical trials are listed, of which 131 are still in progress and 54 were discontinued for various reasons.

Alzheimer's disease market in the seven major markets is analyzed for the year 2012. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2022. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

Profiles of 144 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 97 collaborations. The bibliography contains over 850 publications that are cited in the report.The report is supplemented with 45 tables and 15 figures.

Key Topics Covered:

Executive Summary

1. Clinical Features, Epidemiology and Pathology

2. Diagnostic Procedures for Alzheimer Disease

3. Management of Alzheimer Disease

4. Research in Alzheimer Disease

5. Drug Discovery & Development for Alzheimer Disease

6. Markets & Finances of AD Care<
'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Modeling Alzheimers disease using iPSCs
2. Is There a Natural Cure for Alzheimer's and Other Dementias?
3. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
4. Leuven research opens new pathway for the treatment of Alzheimers disease
5. World Alzheimers Day - 21 September 2012
6. Alzheimers Therapeutics Reviewed by NeuroPerspective
7. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
8. First detailed timeline established for brains descent into Alzheimers
9. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
10. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
11. Scientists gain new understanding of Alzheimers trigger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... ... tear 18 months ago. Conventional treatment and therapy were not working so Zach ... June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow ...
(Date:9/3/2015)... 2015 /PRNewswire/ - bioLytical Laboratories Inc., a leader in ... " Sensitivity of a rapid point of care assay ... affinity for HIV gp41 IgM antibodies " has been ... highlights INSTI,s ability to detect early HIV infection.  ... 8 th annual International AIDS Society Conference, which ...
(Date:9/3/2015)... ... September 03, 2015 , ... Park Systems ... on Sept. 17, 2015 at 9am PST. The webinar will focus on the methods ... known as 3D printing, additive manufacturing is a broad term that encompasses “addition or ...
(Date:9/2/2015)... 2, 2015 Axovant Sciences Ltd. (NYSE:  AXON), a ... today announced upcoming presentations at three investor conferences: ... 2015 Healthcare Conference in New York ... 10 at 2:00 PM at the BioCentury NewsMakers Conference in ... Hotel & Conference Center , Thursday, September 17 at ...
Breaking Biology Technology:UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3
... EVRY, France, May 5 Novagali Pharma, ... the Company,s,Investigational New Drug Application (IND) to ... (Nova21027), for the treatment of glaucoma has ... Administration (FDA). Catioprost(R) is a,topical ocular proprietary ...
... Insmed Inc. (Nasdaq: INSM ), a ... from The NASDAQ Stock Market that it has regained ... requirement, and further, that it currently complies with all ... with the bid price rule, the Company was required ...
... lamps have been used to control outbreaks of measles, ... and hospitals since the 1930,s. UVGI (Ultraviolet Germicidal Irradiation) ... 1955 Mumps epidemic and helped eliminate a Varicella (Chicken ... recently, UVGI units were installed into Hong Kong hospitals ...
Cached Biology Technology:Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2Insmed Regains NASDAQ Compliance 2Swine Flu Fears Generate Interest in UV Disinfection Technologies...Again 2
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... This news release is available in French . ... the Canadian Food Inspection Agency (CFIA), and Alberta Innovates Bio Solutions ... protect consumers from Listeriosis, a serious foodborne illness caused by ... of the University of Alberta, will sequence and map the genomes ...
... a new method for visualizing material defects in thin-film ... Bert Nickel has, for the first time, succeeded in ... cells using laser light for localized excitation of the ... " Advanced Materials ". "We have developed a method ...
... Now, researchers at Yonsei University in Seoul, Republic of ... a layer of silver ions that can prevent growth ... Salmonella typhimurium and Campylobacter jejuni . The ... be particularly useful for applications in disaster recovery and ...
Cached Biology News:New genomics research project to eliminate Listeria from food supply 2Organic electronics: Imaging defects in solar cells 2Spinning up antibacterial silver on glass 2
... The Genome Sequencer 20 System revolutionizes DNA ... parallel fashion. The Genome Sequencer 20 ... Reagents and consumables for library construction, ... mapping and de novo assembly ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... Normal Human Serum-Single Donor • Human ... who are found to be negative by ... (s) (HIV-1Ag), Antibodies to Human Immunodeficiency Virus ... Nonreactive for Hepatitis B Surface Antigen (HbsAg) ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
Biology Products: